Necrotising Enterocolitis Market to grow at a CAGR of 5.5% during 2025 to 2035; Driven by Rising Incidence of Premature Births and Increasing Demand for Advanced Neonatal Care

Necrotising Enterocolitis market Regional Analysis

The Necrotising Enterocolitis Market Size was estimated at 5.44 USD Billion in 2024. The Necrotising Enterocolitis industry is projected to grow from 5.74 USD Billion in 2025 to 9.81 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.5% during the forecast period 2025 - 2035.

The Americas dominated the global Necrotising Enterocolitis (NEC) market owing to the use of numerous therapies for the treatment of Necrotising Enterocolitis (NEC) along with the demand for early diagnosis. For instance, in 2013, Necrotising Enterocolitis (NEC) was the cause of 355 deaths per 100,000 live births in the United States. The death toll was virtually three times higher in the black population than for the white population.

The European region is the second largest market for global Necrotising Enterocolitis (NEC) due to the surging demand for antifungal drugs. Moreover, factors favoring the growth of Necrotising Enterocolitis (NEC) in the Asia Pacific region are the implementation of various healthcare reforms such as Patient Protection and Affordable Care Act (PPACA), increasing investments in the Asia Pacific region offering huge market potential, and rapidly increasing aging population.

The Middle East and Africa is projected to show steady growth in this market due to a subsequent rise in the number of neonatal diseases along with the growing healthcare infrastructure in remote areas.

Segmentation

The global Necrotising Enterocolitis (NEC) market is segmented on the basis of stage, diagnosis, treatment, and end-user.

Based on stage, the market is classified as Stage I, Stage II, and Stage III. The Stage II is further segmented into Stage IIa and Stage IIb. The Stage III is further segmented into Stage IIIa and Stage IIIb.

Based on diagnosis, the market is classified as imaging, laboratory studies, and differential diagnosis. The imaging segment is further classified as abdominal x-ray, Magnetic Resonance Imaging (MRI), ultrasound, laparoscopy, angiography, and others.

The laboratory studies segment is further classified as haemochromocytometric exam, blood culture, serum electrolytes, arterial blood gas analysis, blood pressure monitor, and others. The differential diagnosis segment is further classified as ileus secondary to neonatal sepsis, spontaneous intestinal perforation, ileal atresia, intestinal malrotation, volvulus, neonatal appendicitis, neonatal pseudomembranous colitis, and others.

Based on treatment, the market is classified as Total Parenteral Nutrition (TPN), gastrointestinal decompression, antimicrobial therapy, antifungal treatment, paracentesis, and others.

Based on end-user, the market is classified as hospitals and clinics, ambulatory surgical center, diagnostic centers, and others.

Key Players

Some of the key players in the global necrotising enterocolitis (NEC) market are Abbott Laboratories Inc. (U.S.), Astellas Pharma Inc. (Japan), Bayer HealthCare AG (Germany), Becton, Dickinson and Company (BD) (U.S.), Bristol-Myers Squibb Company (U.S.), Daiichi Sankyo Company , Ltd. (Japan), Eli Lilly and Co. (U.S.), Enzon Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), GI Supply (U.S.), GlaxoSmithKline Plc (UK), Kyorin Pharmaceutical Co., Ltd. (U.S.), Medtronic Plc (U.S.), Merck & Co. Inc. (U.S.), MiddleBrook Pharmaceuticals (Japan), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Sanofi-Aventis (France), Sequana Medical AG (Switzerland), Takeda Pharmaceutical Company, Ltd. (Japan), and others.